Highlighted papers are below, but a complete list is available here.

Christina K. Baumgartner*, Hakimeh Ebrahimi-Nik*, Arvin Iracheta-Vellve, Keith M. Hamel, Kira E. Olander, Thomas G. R. Davis, Kathleen A. McGuire, Geoff T. Halvorsen, Omar I. Avila, Chirag H. Patel, Sarah Y. Kim, Ashwin V. Kammula, Audrey J. Muscato, Kyle Halliwill, Prasanthi Geda, Kelly L. Klinge, Zhaoming Xiong, Ryan Duggan, Liang Mu, Mitchell D. Yeary, James C. Patti, Tyler M. Balon, Rebecca Mathew, Carey Backus, Domenick E. Kennedy, Angeline Chen, Kenton Longenecker, Joseph T. Klahn, Cara L. Hrusch, Navasona Krishnan, Charles W. Hutchins, Jax P. Dunning, Marinka Bulic, Payal Tiwari, Kayla J. Colvin, Cun Lan Chuong, Ian C. Kohnle, Matthew G. Rees, Andrew Boghossian, Melissa Ronan, Jennifer A. Roth, Meng-Ju Wu, Juliette S. M. T. Suermondt, Nelson H. Knudsen, Collins K. Cheruiyot, Debattama R. Sen, Gabriel K. Griffin, Todd R. Golub, Nabeel El-Bardeesy, Joshua H. Decker, Yi Yang, Magali Guffroy, Stacey Fossey, Patricia Trusk, Im-Meng Sun, Yue Liu, Wei Qiu, Qi Sun, Marcia N. Paddock, Elliot P. Farney, Mark A. Matulenko, Clay Beauregard, Jennifer M. Frost, Kathleen B. Yates, Philip R. Kym & Manguso RT. The PTPN2/PTPN1 inhibitor ABBV-CLS-484 unleashes potent anti-tumour immunity. Nature 622, 850–862 (2023). https://doi.org/10.1038/s41586-023-06575-7

Dubrot J*, Du PP*, Lane-Reticker SK, Kessler EA, Muscato AJ, Mehta A, Freeman SS, Allen PM, Olander KE, Ockerman KM, Wolfe CH, Wiesmann F, Knudsen NH, Tsao HW, Iracheta-Vellve A, Schneider EM, Rivera-Rosario AN, Kohnle IC, Pope HW, Ayer A, Mishra G, Zimmer MD, Kim SY, Mahapatra A, Ebrahimi-Nik H, Frederick DT, Boland GM, Haining WN, Root DE, Doench JG, Hacohen N, Yates KB, Manguso RT. In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer. Nature Immunology. 2022 Oct;23(10):1495-1506. doi: 10.1038/s41590-022-01315-x.

Griffin GK*, Wu J*, Iracheta-Vellve A*, Patti JC, Hsu J, Davis TGR, Dele-Oni D, Du PP, Halawi AG, Ishizuka JJ, Kim SY, Klaeger S, Knudsen NH, Miller BM, Nguyen TH, Olander KE, Papanastasiou M, Rachimi S, Robitschek EJ, Schneider EM, Yeary MD, Zimmer MD, Jaffe JD, Carr SA, Doench JG, Haining WN, Yates KB, Manguso RT, Bernstein BE. Epigenetic silencing by SETDB1 suppresses tumour intrinsic immunogenicity. Nature. 2021 Jul;595(7866):309-314. doi: 10.1038/s41586-021-03520-4.

Dubrot J, Lane-Reticker SK, Kessler EA, Ayer A, Mishra G, Wolfe CH, Zimmer MD, Du PP, Mahapatra A, Ockerman KM, Davis TGR, Kohnle IC, Pope HW, Allen PM, Olander KE, Iracheta-Vellve A, Doench JG, Haining WN, Yates KB, Manguso RT. In vivo screens using a selective CRISPR antigen removal lentiviral vector system reveal immune dependencies in renal cell carcinoma. Immunity. 2021 Mar 9;54(3):571-585. doi: 10.1016/j.immuni.2021.01.001.

Ishizuka JJ*, Manguso RT*, Cheruiyot CK, Bi K, Panda A, Iracheta-Vellve A, Miller BC, Du PP, Yates KB, Dubrot J, Buchumenski I, Comstock DE, Brown FD, Ayer A, Kohnle IC, Pope HW, Zimmer MD, Sen DR, Lane-Reticker SK, Robitschek EJ, Griffin GK, Collins NB, Long AH, Doench JG, Kozono D, Levanon EY, Haining WN. Loss of ADAR1 in tumours overcomes resistance to immune checkpoint blockade. Nature. 2019 Jan;565(7737):43-48. doi: 10.1038/s41586-018-0768-9.

Lane-Reticker SK, Manguso RT, Haining WN. Pooled in vivo screens for cancer immunotherapy target discovery. Immunotherapy. 2018 Mar;10(3):167-170. doi: 10.2217/imt-2017-0164.

Manguso RT, Pope HW, Zimmer MD, Brown FD, Yates KB, Miller BC, Collins NB, Bi K, LaFleur MW, Juneja VR, Weiss SA, Lo J, Fisher DE, Miao D, Van Allen E, Root DE, Sharpe AH, Doench JG, Haining WN. In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target. Nature. 2017 Jul 27;547(7664):413-418. doi: 10.1038/nature23270.

Juneja VR, McGuire KA, Manguso RT, LaFleur MW, Collins N, Haining WN, Freeman GJ, Sharpe AH. PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity. J Exp Med. 2017 Apr 3;214(4):895-904. doi: 10.1084/jem.20160801.